Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): A Cancer and Leukemia Group B study

Journal of Clinical Oncology

Volumn 24, Issue 24, 2006, Pages 3904-3911

  Paschka, Peter ^a   Marcucci, Guido ^a   Ruppert, Amy S ^a   Mrózek, Krzysztof ^a   Chen, Hankui ^a   Kittles, Rick A ^a   Vukosavljevic, Tamara ^a   Perrotti, Danilo ^a   Vardiman, James W ^a   Carroll, Andrew J ^a   Kolitz, Jonathan E ^a   Larson, Richard A ^a   Bloomfield, Clara D ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORE BINDING FACTOR; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CLINICAL STUDY; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; EXON; FEMALE; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; ACUTE DISEASE; CHROMOSOME INVERSION; GENE TRANSLOCATION; GENETICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; MYELOID LEUKEMIA; PREDICTION AND FORECASTING; PROGNOSIS; SURVIVAL;

ACUTE DISEASE; ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; INVERSION, CHROMOSOME; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; SURVIVAL ANALYSIS; TRANSLOCATION, GENETIC;

EID: 33748467435     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.9500     Document Type: Article

References (58)

1. Mrózek K, Heerema NA, Bloomfield CD: Cytogenetics in acute leukemia. Blood Rev 18:115-136, 2004
2. Byrd JC, Mrózek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325-4336, 2002
3. Grimwade D, Walker H, Harrison G, et al: The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98:1312-1320, 2001
4. Grimwade D, Walker H, Oliver F, et al: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92:2322-2333, 1998
5. Schoch C, Kern W, Schnittger S, et al: Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): An analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 18:120-125, 2004
6. Slovak ML, Kopecky KJ, Cassileth PA, et al: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/ Eastern Cooperative Oncology Group study. Blood 96:4075-4083, 2000
7. Liu P, Tarlé SA, Hajra A, et al: Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science 261:1041-1044, 1993
8. Erickson P, Gao J, Chang K-S, et al: Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 80:1825-1831, 1992
9. de Bruijn MFTR, Speck NA: Core-binding factors in hematopoiesis and immune function. Oncogene 23:4238-4248, 2004
10. Bloomfield CD, Lawrence D, Byrd JC, et al: Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173-4179, 1998
11. Byrd JC, Dodge RK, Carroll A, et al: Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 17:3767-3775, 1999
12. Byrd JC, Ruppert AS, Mrózek K, et al: Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461. J Clin Oncol 22:1087-1094, 2004
13. Marcucci G, Mrózek K, Ruppert AS, et al: Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): A Cancer and Leukemia Group B study. J Clin Oncol 23:5705-5717, 2005
14. d'Auhol L, Mattel M-G, Andre C, et al: Localization of the human c-kit protooncogene on the q11-q12 region of chromosome 4. Hum Genet 78:374-376, 1988
15. Yarden Y, Kuang W-J, Yang-Feng T, et al: Human proto-oncogene c-kit. A new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6:3341-3351, 1987
16. Yarden Y, Ullrich A: Growth factor receptor tyrosine kinases. Annu Rev Biochem 57:443-478, 1988
17. Roskoski R Jr: Structure and regulation of Kit protein-tyrosine kinase: The stem cell factor receptor. Biochem Biophys Res Commun 338:1307-1315, 2005
18. Lennartsson J, Jelacic T, Linnekin D, et al: Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells 23:16-43, 2005
19. Beghini A, Ripamonti CB, Cairoli R, et al: KIT activating mutations: Incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica 89:920-925, 2004
20. Cairoli R, Beghini A, Grillo G, et al: Prognostic impact of c-KIT mutations in core binding factor leukemias: An Italian retrospective study. Blood 107:3463-3468, 2006
21. Schnittger S, Kohl TM, Haferlach T, et al: KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 107:1791-1799, 2006
22. Shimada A, Taki T, Tabuchi K, et al: KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): A study of the Japanese Childhood AML Cooperative Study Group. Blood 107:1806-1809, 2006
23. Wang Y-Y, Zhou G-B, Yin T, et al: AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci U S A 102:1104-1109, 2005
24. Care RS, Valk PJM, Goodeve AC, et al: Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol 121:775-777, 2003
25. Valk PJM, Bowen DT, Frew ME, et al: Second hit mutations in the RTK/RAS signaling pathway in acute myeloid leukemia with inv(16). Haematologica 89:106, 2004
26. Nanri T, Matsuno N, Kawakita T, et al: Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblasts leukemia harboring t(8;21)(q22; q22). Leukemia 19:1361-1366, 2005
27. Gari M, Goodeve A, Wilson G, et al: C-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol 105:894-900, 1999
28. Hirota S, Isozaki K, Moriyama Y, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580, 1998
29. Rubin BP, Singer S, Tsao C, et al: KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61:8118-8121, 2001
30. Taniguchi M, Nishida T, Hirota S, et al: Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 59:4297-4300, 1999
31. Longley BJ Jr, Metcalfe DD, Tharp M, et al: Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A 96:1609-1614, 1999
32. Nagata H, Worobec AS, Oh CK, et al: Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 92:10560-10564, 1995
33. Fritsche-Polanz R, Jordan J-H, Feix A, et al: Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol 113:357-364, 2001
34. Kemmer K, Corless CL, Fletcher JA, et al: KIT mutations are common in testicular seminomas. Am J Pathol 164:305-313, 2004
35. Nakai Y, Nonomura N, Oka D, et al: KIT (c-kit oncogene product) pathway is constitutively activated in human testicular germ cell tumors. Biochem Biophys Res Commun 337:289-296, 2005
36. Tian Q, Frierson HF Jr, Krystal GW, et al: Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 154:1643-1647, 1999
37. Blechman JM, Lev S, Barg J, et al: The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell 80:103-113, 1995
38. Mitelman F ISCN (1995): An International System for Human Cytogenetic Nomenclature. Basel, Switzerland, Karger, 1995
39. Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896-903, 1994
40. Moore JO, George SL, Dodge RK, et al: Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B study 9222. Blood 105:3420-3427, 2005
41. Kolitz JE, George SL, Barrier R, et al: Treatment of core binding factor (CBF) acute myeloid leukemia (AML) with post-remission high-dose cytarabine (HiDAC): Results from CALGB 9621. Blood 102:176a, 2003 (abstr 612)
42. Kolitz JE, George SL, Dodge RK, et al: Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: Final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol 22:4290-4301, 2004
43. Kolitz JE, George SL, Marcucci G, et al: A randomized comparison of induction therapy for untreated acute myeloid leukemia (AMD in patients < 60 years using P-glycoprotein (Pgp) modulation with Valspodar (PSC833): Preliminary results of Cancer and Leukemia Group B study 19808. Blood 106:122a-123a, 2005 (abstr 407)
44. Cheson BD, Cassileth PA, Head DR, et al: Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813-819, 1990
45. Cross NC, Feng L, Bungey J, et al: Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction. Leuk Lymphoma 11:39-43, 1993 (suppl 1)
46. Al-Ali H-K, Heinrich MC, Lange T, et al: High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J 5:55-60, 2004
47. Frueh FW, Noyer-Weidner M: The use of denaturing high-performance liquid chromatography (DHPLC) for the analysis of genetic variations: Impact for diagnostics and pharmacogenetics. Clin Chem Lab Med 41:452-461, 2003
48. Gray RJ: A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
49. Asn822Lys-mediated signal transduction cascade. Exp Hematol 33:682-688, 2005
50. Cammenga J, Horn S, Bergholz U, et al: Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate. Blood 106:3958-3961, 2005
51. Goemans BF, Zwaan CM, Miller M, et al: Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 19:1536-1542, 2005
52. Kohl TM, Schnittger S, Ellwart JW, et al: KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor. Blood 105:3319-3321, 2005
53. Cairoli R, Beghini A, Morello E, et al: Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations: A report of three cases. Leuk Res 29:397-400, 2005
54. Nanri T, Matsuno N, Kawakita T, et al: Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation. Leukemia 19:1673-1675, 2005
55. Growney JD, Clark JJ, Adelsperger J, et al: Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 106:721-724, 2005
56. Gleixner KV, Mayerhofer M, Aichberger KJ, et al: PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: Comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 107:752-759, 2006
57. Schittenhelm MM, Shiraga S, Schroeder A, et ah Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, luxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 66:473-481, 2006
58. Gotlib J, Berubé C, Growney JD, et al: Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 106:2865-2870, 2005